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Abstract
Background: Improved methods are needed for predicting prognosis and the benefit of delivering adjuvant
chemotherapy (ACT) in patients with non-small-cell lung cancer (NSCLC).
Methods: A novel prognostic algorithm was identified using genomic profiles from 332 stage I-III adenocarcinomas
and independently validated on a separate series of 264 patients with stage I-II tumors, compiled from five previous
studies. The prognostic algorithm was used to interrogate genomic data from a series of patients treated with
adjuvant chemotherapy. Those genes associated with outcome in the adjuvant treatment setting, independent to
prognosis were used to train an algorithm able to classify a patient as either a responder or non-responder to ACT.
The performance of this signature was independently validated on a separate series of genomic profiles from
patients enrolled in a randomized controlled trial of cisplatin/vinorelbine vs. observation alone (JBR.10).
Results: NSCLC patients exhibiting the high-risk, poor-prognosis form of the 160-gene prognosis signature
experienced a 2.80-times higher rate of 5-year disease specific death (log rank P< 0.0001) compared to those with
the low-risk, good prognosis profile, adjusted for covariates. The prognosis signature was found to especially
accurate at identifying early stage patients at risk of disease specific death within 24 months of diagnosis when
compared to traditional methods of outcome prediction.
Separately, NSCLC patients with the 37-gene ACT-response signature (n = 70, 64 %), benefited significantly from
cisplatin/vinorelbine (adjusted HR: 0.23, P = 0.0032). For those patients predicted to be responders, receiving this
form of ACT conferred a 25 % improvement in the probability of 5-year-survival, compared to observation alone
and adjusted for covariates. Conversely, in those patients predicted to be non-responders, ACT was observed to
offer no significant survival benefit (adjusted HR: 0.55, P = 0.32).
The two gene signatures overlap by one gene only SPSB3, which interacts with the oncogene MET. In this study,
higher levels of SPSB3 which were associated with favorable prognosis and benefit from ACT.
Conclusions: These complimentary prognostic and predictive gene signatures may assist physicians in their
management and treatment of patients with early stage lung cancer.
Background
Non-small cell lung cancers (NSCLC), including adeno-
carcinoma, squamous and large-cell tumors, represent
85 % of all lung tumors and result in 1.9 million deaths
each year [1]. While disease stage is associated with out-
come and commonly used to determine adjuvant treat-
ment eligibility, it is known that a subset of patients with
early stage disease experience shorter survival times than
others with the same clinicopathological characteristics.
Improved methods for identifying these individuals, at or
near the time of their initial diagnosis, may support a deci-
sion to pursue an increased frequency of screening or use
of adjuvant therapy options. The ultimate goal of this
work is to provide a tool for generating personalized
assessments of prognosis and adjuvant chemotherapy
(ACT) response, particularly for patients with early stage
disease, in order to reduce the rate of over and under
treatment in NSCLC [2].
Subramanian and Simon recently compared 16 studies
describing the development of prognostic gene expressionCorrespondence: ryan.vanlaar@chipdx.com
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signatures for NSCLC, published between 2002 and 2009
[3]. A standard set of assessment criteria was applied to
each, including an evaluation of study design and statis-
tical analysis methods, and whether the signature demon-
strated an improvement over existing methods of
prognosis. The study concluded that none of the expres-
sion signatures could demonstrate a significant improve-
ment over a clinical formula based on the age and tumor
size, and thus were not useful for clinical application [4].
Heterogeneity of response to ACT significantly con-
founds treatment for patients with NSCLC. As such,
methods are needed to avoid unnecessary treatment in
patients unlikely to respond, despite satisfying the
current treatment guidelines for a given agent or com-
bination of agents. Clinical trials conducted by multiple
groups have shown a potential benefit of cisplatin-
based ACT for individuals with completely resected
tumors, ranging from a 4-15 % survival benefit [5,6].
Unfortunately no significant benefit for patients with
stage I NSCLC has been observed to date, and as such
the standard of care for these patients is surgery and
observation [7].
In a uniquely designed, randomized controlled clinical
trial, Zhu et al. identified 15 genes which stratify patients
into groups distinguished by a significant difference in
both outcome and adjuvant cisplatin/vinorelbine benefit
[8]. While the prognostic ability of the 15-gene algo-
rithm was independently validated using a previously
published series of NSCLC patients, only internal cross-
validation results were presented to verify the signatures
ability to predict response to ACT. While a correctly
conducted cross-validation approach may give an initial
unbiased estimate of classifier accuracy, predictive algo-
rithm validation using at least one external, independent
patient series is recommended [3,9]. Analysis of data
from patients not used in the gene selection and/or
Table 1 Clinicopathological characteristics of the NSCLC patients used in this study (n/a = data unavailable)











65 (10) 64 (10) 62 (10) 69 (9)
Gender: Female,
Male
155 (47 %), 177 (53 %) 141 (53 %), 123 (47 %) 51 (58 %), 39 (42 %) 30 (28 %), 79 (72 %)
AJCC Stage: I: 229 (69 %), II: 61 (18 %),
III: 42 (13 %)
I: 201 (75 %), II: 63 (25 %) I: 39 (44 %), II: 27 (31 %),
III: 21 (24 %), IV: 1 (1 %)
I: 57 (52 %), II: 52 (48 %)
Stage I: A/B 108, 121 93, 97 5, 34 n/a
Stage II: A/B 50, 11 13, 44 25, 3 n/a
Grade:
1/2/3/na
48 (14 %), 163 (49 %),
117 (35 %), 4 (<1 %)
58 (22 %), 94 (35 %),
62 (23 %), 53 (20 %)
10 (11 %), 40 (45 %),








Adenocarcinoma: 47 (43 %),
Large cell: 10 (9 %),
Squamous: 52 (48 %)
Smoking history Never: 33 (10 %)
Former: 181 (55 %),
Current: 25 (8 %),
Unknown: 90 (27 %)
Never: 43 (16 %),
Former/current: 170 (64 %),
Unknown: 54 (20 %)
Never: 14 (16 %)
Former: 65 (74 %)
Current: 7 (8 %)
Unknown: 2 (2 %)
n/a
Radiotherapy 0 13 (5 %) 45 (51 %) 0
Chemotherapy 0 0 88 (100 %) 49 (45 %)
Original publication(s): Sheddon et al. [10] Sheddon et al. [10]
Takeuchi et al. [11]
Zhu et al. [8] Bild et al. [12]
Bhattacharjee et al. [13]
Sheddon et al. [10] Zhu et al. [8]
Genomic platform: Affymetrix U133A Agilent custom array: 59 (22 %),
Affymetrix U95A: 140 (53 %),
U133A/Plus 2.0: 65 (25 %)









122 (37 %) 97 (37 %) 47 (53 %) 34 (31 %)
1https://array.nci.nih.gov/caarray/project/details.action?project.experiment.publicIdentifier=jacob-00182.
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algorithm training allows assessment of the impact of
‘real-world’ technical and biological variation on the per-
formance of a novel multi-gene assay.
Therefore, the goal of this study was to develop and
validate complimentary algorithms for (i) stratifying
stage I-II NSCLC patients into categories with signifi-
cant differences in disease-specific survival (DSS) and
(ii) stratifying stage I-III patients on the basis of
cisplatin-based ACT-benefit, defined as treatment-
related change in DSS. The analytical guidelines pro-
posed by Subramanian and Simon were followed closely
throughout, in order to maximize the clinical relevance
of the novel algorithms developed. Finally, it was
hypothesized that prognosis and sensitivity to ACT
agents may represent independent characteristics of
NSCLC. If this were to be the case, patients with good
or bad prognosis may be equally likely to possess the
molecular characteristics required for ACT-induced
tumor cell death, requiring separate but complimentary
algorithms for the optimal prediction of prognosis and
treatment response.
Methods
Compilation of a genomic database for gene selection &
algorithm training
Genomic and clinical data from 420 patients who were
originally part of The Director’s Challenge Consortium for
Molecular Classification of Lung Adenocarcinoma (DCC)
series (total N=442) were used to identify two sets of
genes associated with (a) disease-specific survival (DSS)
and (b) response to ACT [10]. Patient details for the train-
ing and validation series used in both analyses are sum-
marized in Table 1 and represented schematically in
Figure 1. As reported in the original studies, consent was
obtained for all subjects using protocols approved by each
institution’s Institutional Review Board.
A prognostic algorithm training series was created
using genomic and clinical data from 332 DCC stage IA-
IIIB patients who did not receive ACT or radiotherapy
(Training Series A). This training series included
patients with more advanced NSCLC (Stage IIIB) in
order to capture a broad range of progression-related
genomic information. A separate series of non-ACT
treated 264 stage IA-IIB adenocarcinoma genomic pro-
files (Validation Series A) was compiled from five pub-
lished studies in order to validate the prognostic
signature on an independent series of patients [8,10-13].
Only patients diagnosed with stage IA-IIB NSCLC (and
not used in Training Series A) were selected in order to
reflect the intended use of the prognostic algorithm.
To create a multi-gene signature able to predict re-
sponse to platinum-based ACT, a second training series
was formed using those patients from the NIH Directors
Challenge study who were treated with ACT and with
data available for age at diagnosis, smoking status, tumor
stage and outcome (Training Series B; n = 88, Figure 1).
Sample annotation records indicate that cisplatin-based
ACT was used for 24/88 patients, and although no spe-
cific agent information was available for the other indivi-
duals, presumably a standard-of-care platinum-based
therapy was also used. To validate the predictive mult-
gene signature identified from analysis of Training
Series B, an independent validation series was used.
This was comprised of pre-treatment genomic profiles
from 109 patients with stage I-II disease who were
enrolled in a randomized controlled trial of adjuvant
cisplatin/vinorelbine (n= 49) vs. observation alone (n= 60)
(Validation Series B) [8]. This previously published clin-
ical trial series originally included genomic profiles
from 133 patients; however 24 ACT-treated individuals
were also enrolled in the NIH Directors Challenge
study and were therefore included in Training Series B,
which was used to identify the predictive signature. To
avoid the possibility of bias by training and testing on
data from the same individuals, these 24 patients were
not included in the Validation Series B.
After stratifying patients in Validation Series B into
predicted responders and non-responders, differences in
DSS between those patients receiving ACT or OBS were
compared using Kaplan Meier analysis and multivariate
cox proportional hazards analysis.
Development and validation of a gene expression
signature to predict prognosis in patients with stage I-II
lung adenocarcinoma
Genomic, clinical and outcome data from Training
Series A (n = 332) were analyzed to identify genes with
individual prognostic significance, using a method devel-
oped by Bair and Tibshirani [14] and used previously to
develop prognostic algorithms for breast and colon can-
cer [15,16]. Briefly, genes were selected for inclusion in
the prognostic signature if they were associated with
outcome in Cox regression models at P< 0.001, inde-
pendent to age at diagnosis, smoking history, gender,
histological grade and AJCC stage [17,18]. Using 10-fold
cross-validation, genes found to be significantly asso-
ciated with outcome in two or more rounds of cross-
validation were recorded and then used to train a
principal component algorithm (PCA) [19]. At the
completion of the gene selection process and prior to
training of the final algorithm, expression data for the
prognostic gene set were stabilized by conversion to
percent-rank values, as previously described [15].
The output of the prognostic algorithm is a patient-
specific ‘prognostic index’, ranging from −2.0 to 2.0 and
continuously associated with risk of death from NSCLC,
as reflected in Figure 2. To assign a patient to either a high
or low risk group, their prognostic index is compared to a
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predetermined classification threshold. For this study, the
threshold was set at the 60th percentile of prognostic in-
dexes observed for Training Series A. The prognostic al-
gorithm was independently evaluated by applying it to
data from Validation Series A, which comprised of 264
stage I-II adenocarcinoma patients who were not used in
the gene selection or algorithm training process.
Development and validation of a comparator ‘clinical
algorithm’ for predicting prognosis in patients with early-
stage NSCLC
A key criterion for evaluating NSCLC prognostic gene
expression assays is the ability to improve over current
‘clinical’ methods of identifying patients with stage 1 dis-
ease at high risk of DSS (i.e. poor prognosis). To com-
pare the novel prognostic signature developed herein
with a clinical assessment of prognosis, the approach
described in Subramanian & Simon i.e. a regression
equation based on tumor size (≤3 cm or >3 cm) and age
at diagnosis to predict prognosis was developed [3]. This
algorithm was trained on age and tumor size data using
the stage I patients from Training Series A. Cross-
validation results were compared to those reported by
Subramanian & Simon to ensure equivalency. Finally,
accuracy of the clinical algorithm was evaluated by ap-
plying it to stage I patients from Validation Series A.
Development and validation of a second gene expression
signature to predict adjuvant chemotherapy benefit
Data from Training Series B (n = 88) were analyzed to
select genes associated with outcome (DSS) in the clin-
ical setting of ACT-treatment. To identify genes involved
in ACT-response and not simply prognosis, the covari-
ates included in the Cox regression models were age,
stage, gender, smoking history and prognosis risk group
(P< 0.001), as determined by previously developed prog-
nostic algorithm. A two principal component classifier
was trained on the resulting gene selection, as described
previously. The final classifier was applied to the Valid-
ation Series B, representing 109 patients enrolled in a
randomized controlled trial of ACT vs. OBS [8].
The predictive index generated by this secondary algo-
rithm classifies patients as either ‘ACT-responders’ or
‘ACT-non-responders’, depending on whether the index
is above or below the predetermined classification
threshold (median index of Training Series B). Within
each prediction category, Kaplan Meier analysis with log
rank testing and Cox proportional hazards analysis was
Figure 1 Schematic diagram of datasets used to form training and validation series used in this study. Data from treatment-naïve
adenocarcinoma patients enrolled in the NIH Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma were first
used to develop a prognostic signature able to predict DSS, independent to clinical factors such as age and clinical stage [10]. This signature was
validated on the independent adenocarcinoma series listed and then used to identify a new set of genes from ACT-treated patients that were
associated with outcome, independent to prognosis. The second algorithm (ACT-response) was validated on data from Zhu et al. [8].
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used to compare the rates of DSS for ACT and OBS
treatment arms.
Data processing and probe selection
For Affymetrix datasets, raw CEL files were downloaded
and processed using the MAS5 algorithm. Datasets were
median-centered within each microarray type. NCBI
UniGene build #230 was used to assign gene annotation
data to microarray features and match data between
platforms. Probeset redundancy (where present) was
reduced by identifying the probe with the highest mean
intensity across all samples. Data stabilization was per-
formed using the percentrank method (‘PERCEN-
TRANK’ in Microsoft Excel 2010, ‘ecdf ’ in R) as
previously described [15].
Statistical analysis and software
Gene expression data were analyzed using R 2.12 (www.
r-project.org), Bioconductor [20] and BRB ArrayTools
4.2 [17]. Statistical analyses were performed using Med-
Calc 12.1.1 (MedCalc Software, Mariakerke, Belgium)
and Microsoft Excel 2010 (Microsoft, Redmond, WA).
Kaplan Meier analysis with log rank testing and multi-
variate Cox Proportional Hazards analysis was used to
analyze the significance of prognostic and ACT-response
risk group stratifications, with survival data censored at
60 months for prognosis prediction and 36 months for
treatment response prediction. Receiver Operator Curve
(ROC) analysis was used to compare on the gene expres-
sion and clinical-variable prognostic algorithms.
Results
Identifying genes associated with DSS and prognostic
algorithm training
A cross-validated multivariate cox regression based
method of gene selection was applied to 332 untreated
stage I-III NSCLC whole genomic profiles (Training
Series A) and a set of 160 unique genes was identified
(Additional file 1 Table S5). Each gene was significantly
associated with DSS independent of age at diagnosis,
disease stage and gender at or below P< 0.001 (full list
of genes provided in Additional file 1). Normalized log
intensity values were stabilized by conversion to
percent-rank values (range 0.000 to 1.000) and used to
Figure 2 Association between the 160-gene prognostic signature, clinical and survival information in 301 untreated lung
adenocarcinoma patients from Training Series A patients with at least 12 months follow-up). (A) Prognostic indexes range from −2 to +2
and are associated with an increase in DSS events, as indicated with a black line at (B). (C) Median-centered 160-gene expression profile used to
compute the prognostic index (red= relative high expression, green= relative low expression). Each gene in the signature was chosen based on
its statistically significant association with outcome, independent to age, stage, grade, gender and smoking history.
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train a principal component algorithm able to classify a
new patient as either high or low probability of death
from lung cancer. The relationship between the 160-
gene expression profile, corresponding prognostic index
and the DSS of each patient in Training Series A is
visualized in in Figure 2. A multivariate analysis of the
cross-validated Training Series A risk group predictions
is shown in Additional file 1 Table S1.
Gene ontology characterization of the 160-gene
prognostic signature
Functional characterization of the 160 prognostic genes
was performed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) v6.7
[21]. This system performed clustering of gene annota-
tion terms associated with the 160-gene signature and
showed an over-representation of genes involved in
regulation of metabolic processes (enrichment score:
4.31), cellular organization (1.52), cell cycle control
(1.25) and apoptosis (1.15).
Genes implicated in the MAPK signaling pathway (i.e.
CDC42, MKNK1, MAPKAPK2 and TRADD) were also
over-represented in the gene set, compared to random
selection (P = 0.034). Activation of the MAPK signaling
pathway is linked to the oncogenic factor EAPII (TDP2)
and the development of lung cancer [22].
Only one gene, TRIM14, was found to be in common
between the 160-gene prognosis signature and the 15-
gene signature of Zhu et al. [8]. This is a poorly-
characterized gene that encodes for a protein which
localizes to cytoplasmic bodies [RefSeq, Mar 2010].
Independent validation of the 160-gene prognostic
signature
To determine the ability of the prognostic signature to
predict risk of DSS in patients not involved in the gene
selection or training process, it was applied to data from
an independent series of 264 lung adenocarcinoma
patients with stage I-II disease. These patients were
compiled from five previously published studies, as
described in Table 1 (Validation Series A). After annotat-
ing the gene expression data from each series of patients
with UniGene annotations, it was determined that two
of the microarray platforms present in the combined
series did not contain features that corresponded to all
160 genes that were identified from Training Series A.
The Affymetrix U95A microarray used by Bhattacharjee
et al. [13] contained 132/160 (83 %) of the genes while
the custom Agilent format used by Takeuchi et al. [11]
contained 135/160 (84 %). Rather than impute missing
values using a k-NN method for example, it was decided
to compute the prognostic score using the signature
genes that were available. In this way the validation per-
formed reflects conditions that may occur in real world
use of such a multi-gene assay, in which variations in
specimen preparation and microarray fabrication may
lead to one or more missing data points per signature.
Of the 264 Stage I-II NSCLC patients in Validation
Series A, 174 (66 %) patients were assigned to the low
risk (good prognosis) category and 90 (34 %) to the
high-risk (poor prognosis) category. Kaplan Meier ana-
lysis (Figure 3a) showed the difference in DSS between
risk groups to be highly significant (P = 0.0001, HR: 2.23
95 % CI: 1.46 to 3.50). Furthermore, when adjusted for
other prognostic factors such as age, gender, AJCC
Stage, radiotherapy status and also microarray-type, the
160-gene signature was the strongest and most signifi-
cant predictor of outcome (P< 0.0001, HR: 2.80, 95 %
CI: 1.83 to 4.28, see Additional file 1 Table S1 for more
details).
CPH analysis was also carried out on stage-based sub-
sets of Validation Series A, in order to further
characterize the prognostic significance of the 160-gene
algorithm. Results shown in Table 2 indicate that when
adjusted for covariates, the 160-gene signature is able to
significantly stratify patient with IA, IB and IIA disease,
in addition to stage I and II combined.
Receiver Operator Curve (ROC) analysis also con-
firmed the prognostic index to be a continuous predictor
of outcome (Area Under the Curve (AUC) for all Stage
I-II Validation Series B patients = 0.66, =0.0004, 95 % CI:
0.59 to 0.71), excluding patients alive but with less than
12-months follow-up or death from lung cancer after
36 months. Using a 24 month cut-off for death from
lung cancer, the AUC increases to 0.74 (P< 0.0001, 95 %
CI: 0.67 to 0.80), suggesting increased accuracy at identi-
fying early-stage patients at short term risk of cancer-
related death.
Comparison of gene expression vs. clinical prognostic
algorithms
Utility of new prognostic methods for NSCLC is influ-
enced by their extent of improvement upon currently
accepted approaches. To compare the 160 gene signa-
ture against prognosis based on clinical assessments, an
algorithm based on age at diagnosis and tumor size
(≤3 cm or >3 cm) was developed on the 195 Stage I
patients from Training Series A, using the method
described by Subramanian and Simon [3]. The clinical
algorithm stratified Stage I patients from Validation
Series A (Figure 3D) into groups with statistically signifi-
cant difference in DSS (P = 0.004, HR: 2.65 95 % CI 1.40
to 1.99).
Comparing Kaplan Meier curves for gene expression
and clinical algorithms (Figure 3C-E) illustrates an im-
portant difference between DSS prediction methods; the
160-gene signature is superior to either staging (IA vs.
IB), or the clinical algorithm at identifying stage I
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patients at risk of death within 24 months. Of the 5 Val-
idation Series A patients who were diagnosed with stage
IA cancer and died within 24 months of diagnosis, all
5 were correctly predicted to be high-risk by 160-gene
signature. When the clinical algorithm was applied to
the same patients, only 2 of the 5 were classified as
high-risk. Conversely, none of the stage IA patients
predicted by the gene-signature to be low-risk (n = 65)
died of their disease during the same 24-month time
period (Figure 3E). This ability of the gene signature
to identify early-stage individuals at high risk of death
within a relatively short time frame may represent an
opportunity for clinical intervention, such as the use
of adjuvant chemotherapy.
ROC analysis was also performed to compare the gen-
omic and clinical prognostic algorithms on stage I
patients. For DSS within 5 years following diagnosis,
both methods resulted in a similar AUC (Genomic: 0.66
Clinical: 0.64, P-value for difference: 0.75). When consid-
ering the ability to predict DSS within two years the dif-
ference was more apparent (Genomic: 0.74 Clinical:
0.61, P-value for difference: 0.083). Finally, Cox propor-
tional hazards analysis of stage I patients was performed,
evaluating gender and both genomic and clinical
Figure 3 Kaplan Meier analysis of Validation Series A patients, stratified by gene expression risk group (A) and clinical stage (B). Kaplan
Meier analysis was also performed on Stage IA patients from Validation Series A Stage stratified by AJCC stage (C), a clinical algorithm based on
tumor size and age (D) and the 160-gene signature (C) for comparison purposes. The gene expression signature is able to more accurately
identify stage I patients at risk of death within the first 24 months following diagnosis compared with clinical stage or combined clinical
age + tumor size algorithm.
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algorithms simultaneously. This revealed the gene signa-
ture to be the strongest and most significant predictor of
outcome (genomic algorithm HR: 2.70 95 % CI: 1.55 to
4.65 P = 0.0005, clinical algorithm HR: 2.20 95 % CI: 1.27
to 3.68, P = 0.0047).
Identifying genes related to ACT-response and predictive
algorithm training
To discover genes with patterns of expression correlated
with future response to ACT, a multivariate selection
method was applied to data from 88 ACT-treated adeno-
carcinoma patients (Training Series B). By including
each patient’s previously-determined 160-gene prognosis
score in the gene selection algorithm, a cross-validated
gene selection procedure identified 37 genes to be sig-
nificantly associated with outcome, independent of age,
stage, gender and prognosis (Additional file 1 Table S6).
Kaplan Meier analysis of the (cross validated) Training
Series B risk group assignments made during the train-
ing process revealed a significant difference in DSS be-
tween high and low risk groups (P = 0.0021, HR: 2.48,
95 % CI: 1.40 to 4.42). As all patients in Training Series
B received ACT and the genes selected were related to
outcome independent of prognosis, it was hypothesized
that the difference in DSS between risk groups reflected
the benefit of ACT in these individuals. This hypothesis
was tested by applying the 37-gene signature to Valid-
ation Series B, comprised of individuals enrolled in a
randomized clinical trial of ACT (cisplatin/vinorelbine)
vs. OBS.
Functional characterization of the 37-gene ACT response
signature and overlap with the 160-gene prognosis
signature
Analysis of gene function using DAVID showed the 37-
gene signature contained genes with functions previously
linked to vinorelbine and/or cisplatin efficacy, including
lipid metabolism (eg. LARGE, FA2H, and PCYT1B) [23],
membrane transport (eg. SLC17A1, COX4I1 and
SLC2A1) [24], apoptosis and proliferation (eg. CASP9,
DUSP22 and TBX2) [25] and purine binding (DHX16
and LYN) [26]. An annotated list of the 37 genes, with
Cox regression p-values, is provided in Additional file 1.
Despite starting with the same initial set of gene set,
inspection of both prognostic and predictive algorithms
revealed an overlap of only one gene; splA/ryanodine re-
ceptor domain and SOCS box containing 3 (SPSB3).
SPSB3 has been shown to interact with MET and (based
on protein structure) and is thought to be involved in
ubiquitination and proteasomal degradation [27]. In this
study, patients with good prognosis and predicted to re-
spond to ACT had higher levels of SPSB3 compared to
those with poor prognosis and not likely to respond to
ACT.
The 160 and 37-gene sets were also compared at the
ontology and molecular pathway level using the Fatigo
tool for identifying significant associations between
groups of genes [28]. At the P< 0.05 significance level,
no gene ontologies were significantly represented in both
gene sets (levels 3–9 of ontology structure tested), nor
were any of the KEGG or Biocarta molecular pathways.
Fatigo results are provided in Additional file 2.
None of the 37 ACT-response genes overlapped with
the 15 gene set described by Zhu et al. [8].
Independent validation of the 37-gene predictive
signature
To verify the ability of the novel 37-gene ACT-response
signature, (identified from 88 ACT-treated adenocarcin-
oma patients; Training Series B), to stratify individuals
into groups with different ACT response rates, an inde-
pendent validation series was analyzed. The signature


















Univariate P-value Hazard Ratio (95 % CI) Multivariate P-value Hazard Ratio (95 % CI) P-value AUC (95 % CI)
I & II 264 <0.0001 2.26 (1.46 to 3.50) <0.0001 2.80 (1.83 to 4.28) 0.0004 0.66 (0.59 to 0.71)
I 201 0.0008 2.23 (1.30 to 3.84) <0.0001 3.00 (1.78 to 5.08) 0.0002 0.68 (0.61 to 0.75)
IA 93 0.18 1.76 (0.70 to 4.47) 0.045 2.65 (1.029 to 6.83) 0.019 0.69 (0.59 to 0.78)
IB 97 0.0008 2.79 (1.38 to 5.64) <0.0001 5.44 (2.48 to 11.97) <0.0001 0.75 (0.65 to 0.83)
II 63 0.048 2.00 (0.98 to 4.14) 0.042 2.20 (1.034 to 4.69) 0.56 0.56 (0.42 to 0.70)
IIA 13 0.0097 5.57(1.59 to 19.59) 0.048 28.21 (1.048 to 759.30) 1.0 0.50 (0.17 to 0.83)
IIB 44 0.42 1.47 (0.56 to 3.83) 0.48 1.44 (0.52 to 4.027) 0.57 0.57 (0.40 to 0.58)
Cox Proportional Regression analysis included stage*, microarray type, gender, treatment and age. *where possible, eg.stage IA vs. IB were in the analysis of all
Stage I patients.
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classified 70 patients from Validation Series B ACT-
responders (64 %) and 39 as ACT-non-responders (36 %).
Kaplan Meier analysis showed that the predicted ACT-
responders experienced significantly greater DSS when
treated with ACT, compared to predicted responders who
received observation only (Figure 4). The difference was
significant in both univariate (P= 0.014), and multivariate
analysis (P= 0.0032), adjusted for age, gender, stage and
histology. Inspection of hazard ratios showed that
ACT-responders are at a 3.1-fold (unadjusted for clinical
covariates) or 4.4-fold (adjusted) lower risk of death
within 5-years, when treated with ACT. Full model
results with 95 % CI’s are shown in Additional file 1.
For those individuals assigned to the ACT non-
responders group (n= 39) no statistically significant differ-
ence in DSS was detected between ACT or OBS treat-
ment arms (univariate P = 0.71, multivariate P = 0.38).
Taken together, these findings confirm that the 37-gene
signature can be used to select those individuals likely to
benefit from cisplatin-based chemotherapy, who in this
series represent 64 % of all stage IB-II patients.
Analysis of the stage I/II distribution between the pre-
dicted ACT response groups in Validation Series B con-
firms the findings of other groups that determining
ACT-eligibility using clinical staging results in sub-
optimal outcomes [5]. Thirty-eight of the 70 predicted
ACT-responders were stage I (54 %), a group not usually
considered eligible for ACT. Additionally, just over half
of the Validation Series B patients predicted to be non-
responders were diagnosed with stage II disease (n = 20).
This implies that a quantifiable clinical benefit from
ACT depends on the genomic profile of the tumor, ra-
ther than staging based on conventional assessment.
Comparison of gene expression signatures in paired
fresh-frozen and FFPE tissue
Both genomic signatures developed in this study were
developed using data generated from fresh-frozen
NSCLC tissue. For optimal clinical utility, a test based
on FFPE tissue is preferred as collection of FFPE tissue
is almost universal while frozen tissue is more difficult
to transport and store. A preliminary comparison of the
Figure 4 Kaplan Meier analysis: 37-gene signature treatment response predictions for independent Validation Series B. Patients in (A)
Predicted ‘ACT-responder’ group exhibit significantly improved rate of DSS when treated with ACT compared to OBS alone. Patients in (B)
Predicted ‘ACT non-responder’ group do not exhibit a significant difference in DSS between either treatment arm of the trial. Multivariate Cox
Proportional Hazard analysis included age, gender, stage, NSCLC histological subtype and treatment (ACT or OBS).
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gene sets in paired samples of frozen and FFPE lung tis-
sue was performed using previously published data from
two lung tumors (NCBI GEO: GSE19249) [29]. Frozen
and FFPE sections of each tumor were processed and
hybridized to Affymetrix U133A GeneChips in triplicate.
Passing & Bablok regression was used to compare the
prognostic and predictive indices of the frozen and FFPE
specimens. No significant deviation from index linearity
(P> 0.10) [30], nor change in prognosis/ACT-response
group was observed (see Additional file 1). The linearity
of the 160-gene prognostic index and 37-gene predictive
index observed suggests that these tests may be inform-
ative using FFPE tissue for diagnostic gene expression
analysis, although further validation is required.
Discussion
New methods for predicting outcome (DSS) and re-
sponse to chemotherapy are needed to improve manage-
ment of patients with NSCLC. Two multi-gene
algorithms have been developed to predict DSS and
ACT benefit, using a previously published multi-center
series of lung adenocarcinoma gene expression profiles.
The 160 gene prognostic and 37 gene predictive gene
sets identified by this study overlap by a single gene,
SPSB3, but no functional ontologies or molecular path-
ways were found to be in common. SPSB3 is a largely
uncharacterized gene not previously linked to NSCLC
but in this study found to be associated with good prog-
nosis and benefit from ACT. Several gene ontologies sig-
nificantly represented by the 160 and 37 gene signatures
have been linked to prognosis or ACT efficacy, including
MAPK-pathway regulation, apoptosis, membrane trans-
port and metabolic activity.
The prognostic and predictive signatures developed in
this study differ from previously published methods in a
number of key areas. Both were developed from NSCLC
datasets comprised of a single histological subtype
(NSCLC), using multivariate methods of gene selection
on a large, well annotated training series originally
designed to meet statistical sample-size requirements
[31]. The methods developed in this study satisfy the
Subramanian and Simon [3] criteria for evaluating
NSCLC prognosis signatures (reproduced and annotated
in Additional file 1). These include description of rele-
vant patient characteristics (Table 1), no presentation of
cross-validation statistics as the only performance
metrics and the ability to apply the signature to other
data for future comparisons and other non-clinical uses
(www.ChipDX.com). Finally, the 160-gene prognosis sig-
nature has been shown to stratify stage IA, IB and II
patients into groups with significant differences in RFS
independent of clinical covariates.
The 160-gene prognostic signature was the single
strongest predictor of outcome in patients with stage I
disease when evaluated using multivariate Cox propor-
tional hazards analysis (HR: 2.80, P =<0.0001). Further-
more, as shown by the comparison of ROC data and
also in Figure 3C-E, the genomic method appears to be
superior to other methods at identifying high-risk stage I
patients, i.e. those at risk of death within 24 months.
This may allow clinicians to recommend increased
screening or the use of adjuvant chemotherapy in
patients not otherwise considered eligible.
By evaluating the performance of the 160-gene prog-
nosis signature on a multi-platform multi-center valid-
ation series, it has effectively been ‘stress-tested’ under
conditions resembling real-world use. Despite the fact
that 26 % of samples in Validation Series A were ana-
lyzed using microarrays without the complete 160-gene
set, the classifier was shown to be the strongest pre-
dictor of outcome. Future validation studies using
microarrays containing all 160 genes will help determine
if the signature contains redundant information, or if the
performance statistics generated herein are an underesti-
mate the true prognostic significance of the algorithm.
The 37-gene ACT-response signature was developed
using a novel approach to algorithm design - selecting
genes associated with outcome in ACT treated patients,
independent to a previously calculated prognosis score. By
applying the response signature to an independent valid-
ation series of lung cancer patients who participated in a
randomized clinical trial of cisplatin-based chemotherapy
or observation only, the ability of the algorithm to identify
those who would go on to receive a clinical benefit from
ACT was demonstrated (HR: 0.23; P = 0.0032, adjusted for
clinical covariates). To the contrary, those Validation
Series B patients who were predicted to be non-
responders, showed no difference in DSS between ACT
and OBS arms of the trial (HR: 0.55; P = 0.38). None of the
37 genes overlapped with the 15-gene signature of Zhu
et al. which was reported to have an ACT-benefit hazard
ratio of 0.33 (P= 0.0005) for predicted responders and
3.67 (P= 0.013) for non-responders [8].
The use of ACT in stage I patients is currently contro-
versial [5], however it is proposed that that the method
described herein may allow clinicians to identify and treat
only those individuals whose tumors have the molecular
requirements of ACT efficacy. Prospectively planned trials
and more extensive comparisons of data from frozen and
FFPE tissues, additional NSCLC histologies and che-
motherapeutic agents are necessary to further evaluate the
clinical utility of the algorithms developed.
Conclusions
This study describes novel genomic signatures able to
significantly predict DSS and cisplatin-based ACT bene-
fit for patients diagnosed stage I-II NSCLC. The signa-
tures are comprised of biologically relevant genes and
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have been evaluated on genomic profile data obtained by
multiple institutions using multiple microarray types,
reflecting real-world usage. The distinct composition
and lack of functional overlap of each signature supports
the hypothesis that prognosis and response to ACT in
NSCLC are factors influenced by unique molecular char-
acteristics. In conclusion, robust multi-gene algorithms
have been developed and validated on independent pa-
tient series, demonstrating the potential assist clinicians
improve the management and treatment of patients
diagnosed with NSCLC. Further work is required to con-
firm the findings reported herein and determine the ap-
plicability of these signatures for other lung cancer
histologies and treatment modalities.
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